Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine

Marc Weiner, William Burman, Andrew Vernon, Debra Benator, Charles A. Peloquin, Awal Khan, Stephen Weis, Barbara King, Nina Shah, Thomas Hodge, and the Tuberculosis Trials Consortium

University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX; Denver Public Health and Department of Medicine, University of Colorado Health Science Center and National Jewish Medical and Research Center, Denver, CO; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA; VAMC and George Washington University Medical Center, Washington, DC; and University of North Texas Health Sciences Center, Fort Worth, TX

To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus–seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial. In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration–time curve for 12 hours after the dose [AU_{C_{12}}] was 36 μg · hour/ml in failure/relapse versus 56 μg · hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin. Furthermore, two patients who relapsed with Mycobacterium tuberculosis mono-resistant to rifampicin had very low concentrations of isoniazid. Finally, isoniazid acetylator status determined by N-acetyltransferase type 2 genotype was associated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/rifampin. No rifamycin pharmacokinetic parameter was consistently and significantly associated with outcome (p > 0.10). Because low isoniazid concentrations were associated with failure/relapse, a drug with consistently greater area under the concentration–time curve than isoniazid may be needed to achieve highly active once-weekly therapy with rifapentine.

Keywords: tuberculosis; isoniazid; rifapentine; treatment; pharmacokinetics

Directly observed therapy is one of the key elements of efforts to improve tuberculosis control around the world. Intermittent dosing facilitates directly observed therapy by decreasing the number of required encounters between patient and the treatment provider. The development of rifapentine, a rifamycin antibiotic with a much longer half-life than rifampin (14–15 hours versus 2–5 hours, respectively) was undertaken with the hope that it would allow highly active once-weekly therapy. However, in three large randomized trials (1–3), once-weekly isoniazid/rifapentine was less effective than twice- or thrice-weekly isoniazid/rifampin in the last 4 months of treatment of active tuberculosis.

Two problems were identified in the randomized trials of once-weekly isoniazid/rifapentine: a higher rate of drug-susceptible relapse among human immunodeficiency virus (HIV)-negative patients and a substantial incidence of acquired rifamycin-mono-resistance among the small number of HIV-positive patients treated with this regimen (4). Two theories have been proposed to explain these findings. Mitchison suggested that the dose of rifapentine used in all three trials (600–750 mg) may have been inadequate, analogous to the decreased activity of the 450-mg dose of rifampin, compared with the 600-mg dose, in early clinical trials of that rifamycin (5). However, the occurrence of acquired rifamycin-mono-resistance suggests that the activity of the companion drug, in this case isoniazid, was inadequate to prevent the selection of rifamycin-resistant Mycobacterium tuberculosis. These two theories lead to substantially different interventions to improve the activity of once-weekly therapy: increasing the dose of rifapentine by the former suggestion versus improving the activity of the companion drug in the latter. To evaluate the reasons for decreased activity of once-weekly isoniazid/rifapentine, we evaluated pharmacokinetic parameters of isoniazid, rifapentine, and rifampin among patients enrolled in the Tuberculosis Trials Consortium (TBTC)/United States Public Health Service randomized trial involving this regimen (3). Some of the results of the pharmacokinetic substudy have been previously reported in the form of abstracts (6, 7).

METHODS

Experimental Design

TBTC/United States Public Health Service Study 22 was a randomized trial of once-weekly isoniazid/rifapentine versus twice-weekly isoniazid/rifampin in the continuation phase of treatment in 1,004 HIV-seronegative (3) and 71 HIV-seropositive (4) patients with drug-susceptible pulmonary tuberculosis. The crude rates of failure/relapse were 46/502 (9.2%) in the once-weekly arm and 28/502 (5.6%) in the twice-weekly arm (relative risk 1.64; 95% confidence interval 1.04–2.58; p = 0.04). Patients in Study 22 were enrolled into the pharmacokinetic substudy in two phases. In the retrospective phase, 83 HIV-seronegative patients were enrolled after treatment. Four had failed (had a positive culture between 4 months and the end of therapy) and 33 had relapsed after treatment. Forty-six HIV-seronegative control cases (no evidence of relapse for 2 years after completing therapy) were matched by study site and sex. Retrospective cases underwent sampling after receiving one
TABLE 1. COMPARISON OF THE DEMOGRAPHIC, CLINICAL, AND RADIOGRAPHIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUS–SERONEGATIVE CONTROL CASES AND TREATMENT FAILURE/RELAPSE CASES IN THE PHARMACOKINETIC SUBSTUDY WITH THE OTHER HUMAN IMMUNODEFICIENCY VIRUS–SERONEGATIVE CASES IN THE PARENT STUDY (TUBERCULOSIS TRIALS CONSORTIUM STUDY 22)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All with Treatment Failure or Relapse</th>
<th>All with Cure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients in the PK Substudy, n = 40</td>
<td>Patients Not in the PK Substudy, n = 34</td>
</tr>
<tr>
<td>Age, median yr</td>
<td>39.6 (31.0–50.4)</td>
<td>41.6 (32.5–51.1)</td>
</tr>
<tr>
<td>Sex, percent male</td>
<td>35/40 (88)</td>
<td>27/34 (79)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td>White</td>
<td>17/40 (43)</td>
</tr>
<tr>
<td></td>
<td>African American</td>
<td>12/40 (30)</td>
</tr>
<tr>
<td></td>
<td>Hispanic</td>
<td>6/40 (15)</td>
</tr>
<tr>
<td></td>
<td>Asian</td>
<td>3/40 (8)</td>
</tr>
<tr>
<td>Alcohol (&gt; 1 drink/d)</td>
<td>20/40 (50)</td>
<td>20/34 (59)</td>
</tr>
<tr>
<td>Injection drug use</td>
<td>13/40 (33)</td>
<td>11/34 (32)</td>
</tr>
<tr>
<td>Underweight at enrollment</td>
<td>24/40 (60)</td>
<td>20/34 (59)</td>
</tr>
<tr>
<td>Chest radiographic features</td>
<td>Cavitation</td>
<td>34/40 (85)</td>
</tr>
<tr>
<td></td>
<td>Bilateral involvement</td>
<td>30/40 (75)</td>
</tr>
<tr>
<td></td>
<td>Sputum culture-positive</td>
<td>22/37 (59)</td>
</tr>
</tbody>
</table>

Definition of abbreviations: IQR = interquartile range; PK = pharmacokinetic.
Underweight = weight 10% or more below ideal body weight (3).
Mann-Whitney or χ² statistic for comparisons of continuous or nominal values, respectively.

Sample Collection, Drug, and Genotype Analyses

Blood samples for analyses were collected just before an observed dose and then 1, 2, 5, and 24 hours afterward (and 48 hours for rifapentine). Patients received medications under the same conditions (fasting or fed) that they received their TBTC Study 22 therapy. Standard techniques were used for sample preparation (8), HPLC analyses of plasma drug concentrations (MDS Pharma Services, Montreal, QC), and N-acetyltransferase genotyping (9).

Statistical and Pharmacokinetic Analyses

All primary analyses were performed in 133 HIV-seronegative patients. The primary null hypothesis was that there were no differences in isoniazid or rifamycin pharmacokinetic parameters in HIV-seronegative patients with the endpoints of cure versus failure/relapse.

After establishing the similarity of pharmacokinetic parameters among retrospectively and prospectively sampled patients, we combined these two groups, and for the remainder of the analyses compared all patients with failure/relapse with those who had been cured. We adjusted for rifampin autoinduction. In patients who had not received a dose of rifampin within 14 days before sampling, the estimated rifapin area under the concentration–time curve (AUC₂₋₅) was decreased by 24%, the serum half-life by 44%, and the maximal concentration (Cₘₐₓ) by 4% (10). Isoniazid and rifapentine (11–13) parameters were not adjusted. Analyses of pharmacokinetic parameters were performed using non-compartamental techniques (14, 15). Because a sparse sampling method was used, pharmacokinetic parameters (half-life and AUC₂₋₅) approximated what would have been obtained with more frequent sampling.

Data analyses were performed using SAS software (Cary, NC). Differences between groups were determined using the χ² statistic. The Mann–Whitney U test was used for non-normally distributed data. Differences between groups or correlations between covariates were considered statistically significant at p values less than 0.05. To control for potential confounding factors, proportional hazards analyses were performed using the five factors (3) independently associated with failure/relapse in proportional hazards analysis of the parent trial (positive sputum culture at 2 months of treatment, caviation on chest radiograph, greater than or equal to 10% under ideal body weight, bilateral disease on chest radiograph, and non-Hispanic white race).

RESULTS

Subjects

The demographics and clinical characteristics of the 133 HIV-seronegative patients in the pharmacokinetic substudy were similar to those of all HIV-seronegative patients in Study 22 (Table 1). In the retrospective phase, 4 patients with failure, 33 patients with relapse, and 46 control patients with cure were enrolled. In the prospective phase 50 patients were enrolled, of whom one had failure, two had relapse, and 47 were cured. Combining the retrospective and prospective phases of the study, 54% of the patients (40 of 74) who failed or relapsed in the parent trial underwent pharmacokinetic sampling.

Comparison of Pharmacokinetic Parameters among Retrospectively Sampled versus Prospectively Sampled Patients

To determine if time of sampling affected isoniazid or rifamycin pharmacokinetics, pharmacokinetic parameters were compared among control cases sampled retrospectively to study therapy versus control cases sampled prospectively (Table 2). The control cases were compared in this analysis because only three patients with failure or relapse were sampled prospectively. On initial analysis, all rifampin pharmacokinetic parameters were lower in prospectively sampled patients compared with retrospectively sampled patients. However, after adjustment for rifampin autoinduction, these differences narrowed. The only significant difference in pharmacokinetic parameters was a shorter rifapentine half-life in patients sampled prospectively compared with those sampled retrospectively (median half-life of 14.5 versus 19.5 hours, p = 0.006).
TABLE 2. COMPARISON OF PHARMACOKINETIC PARAMETERS OF ISONIAZID, RIFAMPIN, AND RIFAPENTINE FROM THE CASES WHO WERE CURED AND EITHER SAMPLED RETROSPECTIVELY (AFTER COMPLETING STUDY THERAPY) OR SAMPLED PROSPECTIVELY (DURING STUDY TREATMENT)

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter</th>
<th>Retrospectively Sampled</th>
<th>Prospectively Sampled</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isoniazid</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median AUC&lt;sub&gt;0–12&lt;/sub&gt; (IQR)</td>
<td>54.6 (41.0–86.6)</td>
<td>52.9 (32.2–67.8)</td>
<td>0.22</td>
</tr>
<tr>
<td>Median maximal concentration (IQR)</td>
<td>11.9 (9.6–17.7)</td>
<td>10.4 (7.3–17.0)</td>
<td>0.14</td>
</tr>
<tr>
<td>Median serum half-life (IQR)</td>
<td>2.8 (1.6–3.8)</td>
<td>2.3 (1.5–3.8)</td>
<td>0.59</td>
</tr>
<tr>
<td>Rifampin (no adjustment for autoinduction)</td>
<td>n = 21</td>
<td>n = 19</td>
<td></td>
</tr>
<tr>
<td>Median AUC&lt;sub&gt;0–12&lt;/sub&gt; (IQR)</td>
<td>71.3 (45.1–108.7)</td>
<td>49.7 (43.6–61.4)</td>
<td>0.07</td>
</tr>
<tr>
<td>Median maximal concentration (IQR)</td>
<td>10.7 (5.6–14.0)</td>
<td>6.4 (5.3–10.8)</td>
<td>0.18</td>
</tr>
<tr>
<td>Median serum half-life (IQR)</td>
<td>4.5 (3.1–11.0)</td>
<td>3.8 (3.4–7.0)</td>
<td>0.71</td>
</tr>
</tbody>
</table>

**Rifampin (adjusted for autoinduction)**

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter</th>
<th>Retrospectively Sampled</th>
<th>Prospectively Sampled</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median AUC&lt;sub&gt;0–12&lt;/sub&gt; (IQR)</td>
<td>53.8 (34.0–82.1)</td>
<td>49.7 (43.6–61.4)</td>
<td>0.84</td>
</tr>
<tr>
<td>Median maximal concentration (IQR)</td>
<td>10.3 (5.4–13.4)</td>
<td>6.4 (5.3–10.8)</td>
<td>0.23</td>
</tr>
<tr>
<td>Median serum half-life (IQR)</td>
<td>2.9 (1.8–6.5)</td>
<td>3.7 (3.2–7.0)</td>
<td>0.19</td>
</tr>
</tbody>
</table>

**Rifapentine**

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter</th>
<th>Retrospectively Sampled</th>
<th>Prospectively Sampled</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median AUC&lt;sub&gt;0–12&lt;/sub&gt; (IQR)</td>
<td>207 (139–236)</td>
<td>188 (156–274)</td>
<td>0.88</td>
</tr>
<tr>
<td>Median maximal concentration (IQR)</td>
<td>12.2 (8.0–13.6)</td>
<td>12.0 (9.4–16.5)</td>
<td>0.70</td>
</tr>
<tr>
<td>Median serum half-life (IQR)</td>
<td>19.5 (14.9–24.1)</td>
<td>14.5 (12.2–17.6)</td>
<td>0.006</td>
</tr>
</tbody>
</table>

* p Value by Mann–Whitney rank test; IQR indicates interquartile range.
† Adjustments made to rifampin pharmacokinetic parameters for autoinduction according to Acocella (10).
‡ AUC<sub>0–12</sub> for rifampin and AUC<sub>0–24</sub> for rifapentine.

Association of Pharmacokinetic Parameters with Treatment Outcome

Among patients treated with once-weekly isoniazid/rifapentine, all isoniazid pharmacokinetic parameters (area under the concentration–time curve during 12 hours after dosing [AUC<sub>0–12</sub>], maximal concentration [Cmax] and half-life) were lower among patients with failure or relapse compared with control cases (Table 3). For example, the median isoniazid AUC<sub>0–12</sub> in 22 patients with failure or relapse was 36.0 versus 55.9 µg · hour/ml in 49 patients with cure (p = 0.005, Mann–Whitney U test and Figure E1A in the online supplement). In contrast in 49 patients treated with twice-weekly therapy, isoniazid levels did not significantly differ between failure/relapse and cure (isoniazid AUC<sub>0–12</sub>; p = 0.65, Table 3 and Figure E1A in the online supplement). Of note, isoniazid AUC<sub>0–12</sub> was not significantly different between all cases in the once-weekly treatment arm versus the twice-weekly treatment arm (p = 0.25).

Rifamycin half-lives by univariate analyses were shorter among patients with failure or relapse compared with control cases. However, there was no association between the Cmax or AUC of either rifamycin and treatment outcome. If these analyses were repeated in only patients sampled retrospectively, the same associations between isoniazid and rifamycin pharmacokinetic parameters versus treatment outcome were found (data not shown). Finally, these results were similar when restricted to patients with relapse and cure (i.e., patients with failure excluded; data not shown).

In proportional hazards regression analyses, we adjusted for demographic and clinical factors associated with treatment outcome in the parent trial (a positive sputum culture at 2 months of treatment, cavitation on chest radiograph, being underweight, having bilateral disease on chest radiograph, or being of non-Hispanic white race). In these analyses, isoniazid pharmacokinetic parameters retained their association with failure or relapse, whereas no rifamycin pharmacokinetic parameter was associated with treatment outcome (Table 4). To illustrate the

TABLE 3. COMPARISON OF PHARMACOKINETIC PARAMETERS OF ISONIAZID, RIFAMPIN, AND RIFAPENTINE IN ALL CASES WITH FAILURE/RELAPSE COMPARED WITH CONTROL CASES WITH CURE

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter</th>
<th>Twice-Weekly Isoniazid/Rifampin</th>
<th>Once-Weekly Isoniazid/Rifapentine</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median AUC&lt;sub&gt;0–12&lt;/sub&gt; (IQR)*</td>
<td>43.3 (23.1–81.5)</td>
<td>36.0 (25.2–56.2)</td>
<td>0.005</td>
</tr>
<tr>
<td>Median maximal concentration (IQR)</td>
<td>48.8 (30.9–66.7)</td>
<td>55.9 (41.1–86.6)</td>
<td></td>
</tr>
<tr>
<td>Median serum half-life (IQR)</td>
<td>11.9 (6.1–14.6)</td>
<td>11.9 (9.5–18.6)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Rifampin†

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter</th>
<th>Twice-Weekly Isoniazid/Rifampin</th>
<th>Once-Weekly Isoniazid/Rifapentine</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median AUC&lt;sub&gt;0–12&lt;/sub&gt; (IQR)†</td>
<td>46.1 (35.8–49.3)</td>
<td>41.1 (34.6–58.9)</td>
<td>0.02</td>
</tr>
<tr>
<td>Median maximal concentration (IQR)</td>
<td>50.5 (38.2–72.9)</td>
<td>55.9 (41.1–86.6)</td>
<td></td>
</tr>
<tr>
<td>Median serum half-life (IQR)</td>
<td>2.1 (1.6–3.5)</td>
<td>2.4 (1.5–3.7)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

† p Value by Mann–Whitney rank test; IQR indicates interquartile range.
‡ Adjustments made to rifampin pharmacokinetic parameters for autoinduction according to Acocella (10).
AUC<sub>0–12</sub> for rifampin and AUC<sub>0–24</sub> for rifapentine.

Definition of abbreviations: AUC<sub>0–12</sub> = area under the concentration–time curve for 12 hours after the dose; IQR = interquartile range.
TABLE 4. ASSOCIATION BETWEEN PHARMACOKINETIC PARAMETERS AND OUTCOME BY TREATMENT ARM WITH AND WITHOUT ADJUSTMENT FOR OTHER RISK FACTORS FOR TREATMENT FAILURE/RELAPSE IN HUMAN IMMUNODEFICIENCY VIRUS–SERONEGATIVE PATIENTS

<table>
<thead>
<tr>
<th></th>
<th>Univariate (Continuous PK Parameters and Dichotomous Other Risk Factors)</th>
<th>Multivariate (Continuous PK Parameters and Dichotomous Other Risk Factors)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hazard Ratio (95% CI) p Value</td>
<td>Hazard Ratio (95% CI) p Value</td>
</tr>
<tr>
<td>Model with isoniazid AUC0–12 and rifapentine half-life, n = 76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoniazid AUC0–12</td>
<td>1.02 (1.01–1.04) 0.009</td>
<td>1.03 (1.01–1.05) 0.001</td>
</tr>
<tr>
<td>Rifapentine half-life</td>
<td>1.14 (1.02–1.27) 0.02</td>
<td>0.46</td>
</tr>
<tr>
<td>Culture (+) at 2-months</td>
<td>7.16 (2.93–17.46) &lt;0.0001</td>
<td>3.08 (1.07–8.87) 0.04</td>
</tr>
<tr>
<td>Lung cavity</td>
<td>5.60 (1.66–18.89) 0.006</td>
<td>4.22 (1.06–16.79) 0.04</td>
</tr>
<tr>
<td>Underweight</td>
<td>2.73 (1.17–6.35) 0.02</td>
<td>3.89 (1.45–10.44) 0.007</td>
</tr>
<tr>
<td>White non-Hispanic</td>
<td>2.16 (0.94–4.95) 0.07</td>
<td>2.84 (1.13–7.17) 0.03</td>
</tr>
<tr>
<td>Bilateral lung disease</td>
<td>1.30 (0.55–3.06) 0.55</td>
<td>0.34</td>
</tr>
<tr>
<td>Model with isoniazid AUC0–12 and rifampin AUC0–12, n = 57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoniazid AUC0–12</td>
<td>1.00 (0.99–1.02) 0.82</td>
<td>0.65</td>
</tr>
<tr>
<td>Rifampin AUC0–12</td>
<td>1.12 (0.90–1.39) 0.30</td>
<td>0.34</td>
</tr>
<tr>
<td>Culture (+) at 2-months</td>
<td>4.17 (1.54–11.31) 0.005</td>
<td>4.52 (1.52–13.47) 0.007</td>
</tr>
<tr>
<td>Lung cavity</td>
<td>3.03 (0.87–10.56) 0.08</td>
<td>0.58</td>
</tr>
<tr>
<td>Underweight</td>
<td>3.08 (1.17–8.10) 0.02</td>
<td>3.30 (1.12–9.74) 0.03</td>
</tr>
<tr>
<td>White non-Hispanic</td>
<td>2.04 (0.78–5.37) 0.15</td>
<td>0.74</td>
</tr>
<tr>
<td>Bilateral lung disease</td>
<td>5.98 (1.37–26.21) 0.02</td>
<td>0.18</td>
</tr>
</tbody>
</table>

*Definition of abbreviations: AUC0–12 = area under the concentration–time curve during 12 hours after dosing; CI = confidence interval.

In the multivariate proportional hazards models, covariates with a probability < 0.15 were entered in a stepwise procedure with the isoniazid AUC0–12 (continuous variable), rifampin AUC0–12 adjusted for autoinduction (continuous variable) or rifapentine half-life (continuous variable), sputum culture after 2-months treatment for Mycobacterium tuberculosis (positive or negative), underweight at 2 months (yes or no), radiographic lung cavities at baseline or 2-months treatment (present or none), white non-Hispanic race (yes or no) and bilateral lung disease (yes or no). Hazard ratios expressed for the continuous AUC0–12 parameter for a decrease \( \frac{1}{\mu g \cdot hour/ml} \), and half-life for a decrease of 1 hour.

N-acetyltransferase Type 2 Genotype and Treatment Outcome

Isoniazid acetylator status was determined by N-acetyltransferase type 2 (NAT2) genotype in 89 HIV-seronegative cases (Table 5). NAT2 phenotype, as determined by genotype, was associated with outcome in cases treated with once-weekly isoniazid/rifapentine compared with all control cases with cure (p = 0.03, \( \chi^2 \)). By contrast, phenotype in cases treated with twice per week isoniazid/rifampin was not significantly associated with outcome (p = 0.18). Of note, there was a highly significant association between NAT2 phenotype and isoniazid AUC0–12 (p < 0.0001).

Relapse of M. tuberculosis Monoresistant to Rifamycin in Two Patients with Low Isoniazid Concentrations

Five patients relapsed with M. tuberculosis monoresistant to rifamycin in the TBTC Study 22 (3, 4). Four of these patients were coinfected with HIV and were treated with once-weekly isoniazid/rifapentine; the fifth patient was HIV-seronegative and was treated with twice-weekly rifampin. Two of the five cases in TBTC Study 22 with acquired rifamycin-resistant relapse had...
pharmacokinetic sampling performed (Figure 1A) in the sub-
study; both had very low concentrations of isoniazid at all time 
points and low pharmacokinetic parameters. Of note, rifampin 
concentrations were obtained from the HIV-negative patient, 
and in this case rifampin concentrations were comparable with 
those obtained from all other patients (Figure 1B).

**Association of Pharmacokinetic Parameters with **
**Treatment Outcome in HIV-Seropositive Patients**

Of the 33 HIV-seropositive patients in the pharmacokinetic 
study, 4 relapsed and 29 were cured. The median CD4 cell count 
at the time of the pharmacokinetic study was 240 cells/mm³ 
(interquartile range 166–383), the median viral load was 11,244 
copies/mm³ (interquartile range 593–69,083).

Because prior studies of tuberculosis treatment outcomes and 
pharmacokinetic parameters were evaluated in HIV-seronega-
tive patients and because the number of HIV-seropositive pa-
tients in this pharmacokinetic substudy was small, all primary 
analyses were done in the HIV-seronegative population. In sec-
ondary analyses with the 33 HIV-seropositive cases, the findings 
remained the same. In 18 HIV-seropositive cases treated with 
once-per-week therapy, the median isoniazid AUC₀–₁₂ was lower 
in 2 patients who relapsed versus 16 control cases (AUC₀–₁₂ 23.8 
vs. 60.6 µg · hour/ml, p = 0.16, Mann–Whitney). By comparison, 
in the 15 HIV-seropositive patients treated twice per week with 
isoniazid and rifampin, the median isoniazid AUC₀–₁₂ was similar 
in two cases with relapse versus the 13 control cases (41.9 versus 
48.7 µg · hour/ml, p = 0.87). Furthermore, the association of phar-
macokinetic parameters with treatment outcome remained the 
same if all HIV-seropositive and HIV-seronegative cases were 
analyzed together (n = 152 with isoniazid AUC₀–₁₂ determined). 
Specifically, median isoniazid AUC₀–₁₂ in 88 cases receiving 
twice-weekly isoniazid and rifapentine was lower in 24 patients 
with failure or relapse versus 64 cures (AUC₀–₁₂ 34.9 versus 56.2 µg · 
hour/ml, p = 0.002). As before, the median isoniazid AUC₀–₁₂ 
in the 64 cases receiving twice-weekly isoniazid and rifampin 
were similar in 18 patients with failure or relapse and the 46 
cures (AUC₀–₁₂ 43.3 versus 48.7 µg · hour/ml, p = 0.7).

**DISCUSSION**

Three independent lines of evidence in this study suggest that 
isoniazid pharmacokinetics explain at least part of the decrease 
in efficacy of the once-weekly isoniazid/rifapentine regimen.

First, there was a strong relationship between several isoniazid 
pharmacokinetic parameters and the occurrence of failure or 
relapse among patients treated with once-weekly therapy. This 
association remained strong after adjustment for demographic 
and clinical risk factors for failure or relapse. Second, an inde-
pendently analyzed marker of isoniazid pharmacokinetics, the 
presence of NAT2 genotypes that more rapidly metabolize isoniazid, 
was also associated with failure or relapse among patients treated 
with once-weekly therapy. Finally, the finding that all cases of 
acquired resistance had acquired rifamycin-monoresistance is 
strong evidence of a deficiency of isoniazid. Although anecdotal, 
it is interesting that in the two such cases included in this study, 
isoniazid concentrations were very low.

These findings are somewhat surprising because isoniazid has 
long been believed to play a minor role in the efficacy of rifam-
pin-based tuberculosis treatment, particularly after the first 2 
months of therapy. In a variety of clinical trials in which standard-
ized rifampin-based regimes were used without knowledge of 
initial drug-susceptibility patterns, isoniazid resistance appeared 
to have little effect on the rate of relapse. Specifically, although 
the number of patients was low, baseline isoniazid resistance 
was not a risk factor for failure or relapse among patients in the 
Hong Kong trial (1, 16, 17) of once-weekly isoniazid/rifapentine 
(2/16 [12.5%] having isoniazid-resistant isolates relapsed versus 
38/346 [11.0%] of those with isoniazid-susceptible isolates). Fur-
thermore, in the Hong Kong trial, rapid acetylators of isoniazid 
(determined by NAT2 genotyping) were not at higher risk of 
failure or relapse.

Despite the impressive evidence suggesting that isoniazid plays a 
minor role in standard twice-weekly rifampin-based therapy, 
evidence from several sources suggests that this conclusion 
may not be true for once-weekly therapy. In the British Medical 
Research Council Singapore trial of once-weekly regimes of 
isoniazid and rifampin (18), rapid acetylators of isoniazid were 
not at greater risk of failure (12/155 rapid acetylators [8%], but 0/
117 slow acetylators) but not of relapse. Furthermore, in a mouse 
model of tuberculosis treatment that has correlated closely with 
the results of human clinical trials, once-weekly therapy with 
isoniazid/rifapentine was associated with a low risk of acquired 
rifampycin-monoresistance (19). In further experiments (20) in-
volving once-weekly rifapentine-based regimes, the occurrence of 
acquired rifamycin-monoresistance was prevented by supple-
menting the regimen with daily isoniazid or weekly moxifloxacin but not by increasing the dose of rifapentine.

Despite similar overall rates of failure/relapse in the two treatment arms, there were significant differences between the Hong Kong trial and TBTC Study 22 cohorts in risk factors for failure/relapse. Two-month culture positivity was detected in only 8.2% of 522 cases from Hong Kong (1, 16, 17) versus 20% of 886 in TBTC 22 (p < 0.0001). Radiographic lung cavitation was identified in 37% of 592 cases from Hong Kong versus 54% of 975 in TBTC 22 (p < 0.0001). These two differences suggest that patients enrolled in TBTC 22 may have had more advanced disease than the population in the Hong Kong trial. This difference in disease severity may, in part, account for the different conclusions about the role of isoniazid.

Finally, it is notable that the isoniazid pharmacokinetic parameter having the strongest association with treatment failure or relapse was AUC, not Cmax (Table 3). This finding is consistent with the results in early studies of once-weekly isoniazid plus streptomycin, in which increasing the isoniazid dose among rapid acetylators (which increased the Cmax, but had much less effect on AUC) did not alter their increased risk of treatment failure (21, 22). Both results suggest that time over a critical concentration (as approximated by AUC) is a more important determinant of the success of highly intermittent isoniazid therapy than is peak drug concentration (Cmax).

An important negative finding in this study was the lack of consistent association between pharmacokinetic parameters and the occurrence of failure or relapse in HIV-seronegative patients given twice-weekly isoniazid and rifampin. Prior uncontrolled studies (23, 24) have reported low serum concentrations of rifam-pin among patients who had failure or relapse with standard rifampin-based regimens. These studies have been interpreted as demonstrating that abnormal pharmacokinetics were an important cause of poor outcome with standard therapy. However, these studies had major methodological problems. The most serious problem was the lack of pharmacokinetic data from a control population of patients who were cured. In addition, these studies assessed only one or two time points and thus may have substantially underestimated the peak serum concentration, the pharmacokinetic parameter said to be abnormal. Our study—with more data points per patient and inclusion of pharmacokinetics among controls—found no consistent relationship between the pharmacokinetics of isoniazid and rifampin and failure or relapse. Although exceptions may occur at extreme values (as exemplified by the case of acquired rifamycin-resistance in an HIV-negative person treated with twice-weekly rifampin plus isoniazid), our data suggest that serum concentrations of isonia-zid and rifampin achieved in the vast majority of patients are not associated with failure or relapse. Among patients treated with standard isoniazid and rifampin therapy, failure and relapse may reflect other host factors (pulmonary cavitation, for example) (3) and perhaps pathogen-related factors (such as drug tolerance) (25) rather than “low” serum concentrations of isoniazid and rifampin. Additional research is required to define the role of each of these variables, particularly during the first 2 months of treatment.

This pharmacokinetic substudy has several important limitations. Many of the patients had pharmacokinetic sampling performed after completing their initial course of treatment. It is possible that pharmacokinetic parameters among these patients would have been different if they had been sampled during the course of treatment. However, in the limited number of subjects in other studies who have had pharmacokinetic determinations on more than one occasion, there was relatively little intrapatient variability (11–13, 26). In addition, after adjustment for the well-described effects of rifampin autoinduction, pharmacokinetic parameters of patients sampled prospectively were quite similar to those of patients sampled retrospectively in this study. Thus, it was unlikely that our use of retrospective sampling resulted in a systemic bias in this analysis. Our sampling scheme (five time points per patient) was not sufficient to determine some pharmacokinetic parameters, like half-life, with a high degree of accuracy. However, the robustness of the findings suggests that this sampling scheme was sufficient to detect relevant differences in pharmacokinetic parameters. Residual confounding by measured or unmeasured variables is possible, but the risk factors for failure or relapse identified in the 1,004 patients in TBTC Study 22 were used to adjust relative risk in multivariate analyses. Finally, our study did not use all possible restriction enzymes to detect slow acetylator genotypes. Unfortunately, the NAT2 genetic analysis was incomplete; two mutations—G191A and A341C with frequencies in African Americans of 9 and 6%, respectively (9)—could not be detected. In the study, 4 of 22 African Americans were discordant between phenotype determined by drug pharmacokinetic sampling and by NAT2 genotype. However, detection of these mutations in the four discordant cases would have changed the genotype designations so as to further support the association of NAT2 genotypes with failure/relapse with once-weekly isoniazid/rifapentine but not twice-weekly isoniazid/rifampin.

In summary, our study offers strong evidence that isoniazid plays a significant role in once-weekly rifapentine/isoniazid therapy. Increasing the dose of rifapentine (27) may also increase the potency of once-weekly therapy, as suggested by the mouse model, but is unlikely to result in highly active therapy that completely prevents acquired rifamycin-resistance. The implication of this finding is that efforts to strengthen once-weekly therapy should include some alteration to the nonrifamycin portion of the regimen. Interventions that may be effective include adding a drug with a longer half-life, such as moxifloxacin, or supplementing the regimen with daily isoniazid. Finally, these results illustrate the usefulness of incorporating pharmacokinetic measurements into studies evaluating new treatment regimens.

CONTRIBUTORS
The participating clinical sites (principal investigators and study co-ordinators [numbers of patients enrolled]) were: University of North Texas Health Science Center (Stephen Weis, D.O., Barbara King, R.N., [33]), New Jersey Medical School National TC B-ter-University of Medicine and Dentistry of New Jersey (Lee B. Reichman, M.D., M.P.H., Bonita T. Mangura, M.D., Saundra Barnes, R.N., Marilyn Owens, R.N. [14]), Emory University School of Medicine (C. Robert Horsburgh, M.D., Ben Barnett, M.D., Naomi Bock, M.D., Sue Ann Brenner, M.D., Edith Woodward-Aaron, R.N., Carlos Franco-Paredes, M.D., Lorraine N. Alexander, R.N., M.P.H. [13]), University of Manitoba (Earl Hershfield, M.D., Gerry Izon, R.N. [12]), Houston VA Medical Center (Christopher Lahart, M.D., Ruby Nickson, R.N., Terry Scott, R.N., Robert Awe, M.D. [12]), Johns Hopkins University School of Medicine (Richard Chaisson, M.D., Kristina Moore, R.N., Walt Jones, R.N., Judith Hackman, R.N. [10]), Los Angeles County/University of Southern California Medical Center (Brenda Jones, M.D., Claudia Silva, R.N. [9]), University of Texas Health Science Center in San Antonio/South Texas Veterans Health Care System (Marc Weiner, M.D., Dorothy Phillips, R.N., Alma Quintero, R.N., Karen Eley, R.N. [9]), Harlem Hos-pital Center (Wafaa El-Sadr, M.D., Waref Azmeh, M.D., Frantz Medard, M.D., Sandra Barnaby, R.N. [7]), Veterans Affairs Medical Center-Washington DC (Fred Gordin, M.D., Debra Benator, M.D., Donna Sepulveda Conwell, R.N., Thomas Walsh, M.D., Margaret Lankford, R.N., Charlotte Quinlan-Mauzy, R.N. [7]).
Bellevue Hospital Center, New York University (Neil Schluger, M.D., William Rom, M.D., Rany Condos, M.D., Laurie Sandman, R.N., M.P.H. [7]), Chicago VA Medical Center-Westside (David Pitrak, M.D., Mary Jo Werhane, R.N., Marilyn Szekendi, R.N. [7]), Denver Health and Hospitals (Randall Reves, M.D., William Burman, M.D., Jan Tapy, R.N. [6]), McClellan VA Hospital, Little Rock (Rebecca Edge Martin, M.D., Katherine Hayden, R.N. [5]), Maricopa Medical Center Research Foundation (Maricella Moffitt, M.D., Debra Smith, R.N., Wenda Attwood, R.N. [5]), Chicago VA Medical Center-Lakeside (Mondira Bhat-tacharya, M.D., Julie Fabre, R.N. [4]), University of California San Diego Medical Center (Antonino Catanzaro, M.D., Muppy Haigler, R.N., Sue Ann DiProfoio, R.N., P.H.N., Peach Francisco, R.N., Philip Lobue, M.D., Diane Havlir, M.D. [4]), VA Greater Los Angeles Healthcare System (Matthew Goetz, M.D., Felicitas Lorenzo, R.N. [4]), New York VA Medical Center (Michael Simberkoff, M.D., Yvonne Francis, R.N. [4]), Duke University Medical Center and Durham VA Medical Center (Carol Dukes Hamilton, M.D., Ann Mosher, R.N. [3]), Hines VA Medical Center and Suburban Cook County TB District, Illinois (Constance Pachuki, M.D., Mary Samuel, R.N., James Gallai, M.D. [2]), Nashville VA Medical Center (Douglas Kernodle, M.D., Anthony Chapdelaine, M.D., Linda Reeves-Hammock, R.N. [3]), Carolinas Medical Center (James Horton, M.D., Ann Boye, R.N., Beth Quinn, R.N. [2]), San Francisco VA Medical Center (Peter Jensen, M.D., Llewellyn Stanton, R.N. [1]), and Chicago Department of Public Health (William Paul, M.D., Rosalie Czyrner, R.N. [1]).

Acknowledgment: The authors are grateful to the patients who contributed to the success of this trial, to Drs. Rick O’Brien and Kenneth Castro for their support and leadership within CDC, to Ms. Lorna Bozeman and Diane Pizzaro for assistance with study logistics, to Dr. Anther Keung for his insights on rifapentine pharmacokinetics, to Mr. Daniel Mongrain and John Korontzis of MDS Pharma for HPLC measurement of plasma drug levels, and to Drs. C. Robert Horsburgh and Randall Reves for their review of the manuscript.

References
23. Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM. Utility of rifapmin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;120:1520–1524.